Featured Research

from universities, journals, and other organizations

Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women, study finds

Date:
September 26, 2011
Source:
ECCO-the European CanCer Organisation
Summary:
A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women. The overall survival rate in post-menopausal women was 85 percent compared to 79 percent for women who did not receive zoledronic acid. Researchers in the multi-center AZURE trial think it could be the key for a greater understanding of the mechanisms of breast cancer recurrence.

A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress. Researchers think it could be the key for a greater understanding of the mechanisms of breast cancer recurrence as well as offering new options for patient care.

Zoledronic acid is one of the bisphosphonates, a group of drugs mainly used to treat osteoporosis. However they are also given to cancer patients to protect against the effects of secondary bone cancer, such as pain and weakness in the bones. Laboratory studies have suggested that zoledronic acid might also have direct anti-tumour effects and enhance other chemotherapy treatments, so the multi-centre AZURE trial was set up to investigate further.

Led by Professor Robert Coleman at the Weston Park Hospital in Sheffield, UK, the trial recruited 3,360 patients with stage II/III breast cancer from 174 centres. They were randomised to receive chemotherapy and/or endocrine therapy, with or without zoledronic acid. An interim analysis of the trial's progress indicated that patients were seeing no clinical benefit from the treatment, so the data were released for more detailed scrutiny.

This confirmed the drug's lack of impact, apart from in a sub-set of women who had undergone menopause five or more years previously. Here, the overall survival rate was 85% compared to 79% for women who did not receive zoledronic acid. The effect was independent of the characteristics of the disease as shown by the stage of the tumour, oestrogen receptor status, and lymph node involvement.

"This is a small but significant increase," Prof Coleman explains. "The finding is not sufficient to be taken up on its own but in the context of other studies and additional data anticipated later in the year, it is likely to change practice."

The results shed new light on the role that the bones may play in the progress of the disease. "The effects on metastasis and recurrence outside bone suggests that the bone marrow is an important sanctuary for tumour cells which can be activated after, sometimes, many years of dormancy," Prof. Coleman says. "With help from bone marrow stem cells, they may then spread via the blood stream to set up metastases at other sites."

Even if this is the case, it is still not clear why zoledronic acid is having a beneficial effect. Prof Coleman speculates that it may alter the balance of substances such as cytokines and growth factors that control the bone marrow micro-environment. In this altered state the ability of cancer cells to leave the bone marrow and move to other parts of the body may become dependent on the presence of reproductive hormones. "Presumably, these changes are only clinically relevant in the context of low levels of female reproductive hormones that we see after menopause," he says.

Further work will be required to establish whether or not this is the case. "We plan to use new, more clinically relevant, animal models of metastasis to assess the early events in the spread of cancer and effects of treatments like zoledronic acid," Prof Coleman says.

Dr Coleman's presentation to the congress coincides with the simultaneous publication of a paper about the research in the New England Journal of Medicine.

President of ECCO, Professor Michael Baumann, said: "It is important to note that so-called 'negative trials', that is trials that do not show the anticipated improvement in the endpoint selected, can yield very important information for further trials and also can feed important information back into preclinical research. Eventually negative trials, even if initially very disappointing for the investigators, can make important contributions to cancer research and to practice-changing new strategies relevant for cancer patients."

Commenting on the study, which he was not involved with, ESMO member Professor Christoph Zielinski from the Medical University of Vienna, Vienna, Austria, said: "Whereas the earlier data from the AZURE trial did not show any influence of zoledronic acid upon outcomes in an unselected patient population, the present results show that post-menopausal patients do benefit from this treatment approach. These data are similar to the ABCSG 12 data reported earlier in which hormonal medication was given to premenopausal patients to induce premature menopause. Taken together, the two trials thus add up to a high level of evidence of a benefit of the addition of zoledronic acid to adjuvant therapy for early breast cancer in either naturally or medically induced postmenopausal women."


Story Source:

The above story is based on materials provided by ECCO-the European CanCer Organisation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert E. Coleman, Helen Marshall, David Cameron, David Dodwell, Roger Burkinshaw, Maccon Keane, Miguel Gil, Stephen J. Houston, Robert J. Grieve, Peter J. Barrett-Lee, Diana Ritchie, Julia Pugh, Claire Gaunt, Una Rea, Jennifer Peterson, Claire Davies, Victoria Hiley, Walter Gregory, Richard Bell. Breast-Cancer Adjuvant Therapy with Zoledronic Acid. New England Journal of Medicine, 2011; 110925050012003 DOI: 10.1056/nejmoa1105195

Cite This Page:

ECCO-the European CanCer Organisation. "Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women, study finds." ScienceDaily. ScienceDaily, 26 September 2011. <www.sciencedaily.com/releases/2011/09/110925125153.htm>.
ECCO-the European CanCer Organisation. (2011, September 26). Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/09/110925125153.htm
ECCO-the European CanCer Organisation. "Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/09/110925125153.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Bone Drug Is Mixed Blessing for Breast Cancer Patients

Sep. 26, 2011 A drug used to protect bone may extend survival in older breast cancer patients, according to researchers. The AZURE trial has revealed that the bisphosphonate drug zoledronic acid boosts ... read more
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins